DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk by Bernard-Gallon, Dominique et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Molecular Cancer
Open Access Research
DNA repair gene ERCC2 polymorphisms and associations with 
breast and ovarian cancer risk
Dominique Bernard-Gallon1,2, Rémy Bosviel1,2, Laetitia Delort1,2, 
Luc Fontana3,4, Alain Chamoux3,4, Nadège Rabiau1,2, Fabrice Kwiatkowski1,2, 
Nasséra Chalabi1,2, Samir Satih1,2 and Yves-Jean Bignon*1,2,3
Address: 1Département d'Oncogénétique du Centre Jean Perrin, EA 2416 CBRV, 28 Place Henri Dunant, B.P. 38, 63001 Clermont-Ferrand Cedex 
01, France, 2CRNH, 58 rue Montalembert, 63009 Clermont-Ferrand Cedex 01, France, 3Univ Clermont 1, UFR Médecine, Institut de Médecine du 
Travail, 28 place Henri Dunant, 63001 Clermont-Ferrand, France and 4CHU Clermont-Ferrand, Service Santé Travail Environnement, 28 place 
Henri Dunant, 63001 Clermont-Ferrand cedex, France
Email: Dominique Bernard-Gallon - Dominique.Bernard-Gallon@cjp.fr; Rémy Bosviel - remy.bosviel@caramail.com; 
Laetitia Delort - delort.laetitia@neuf.fr; Luc Fontana - Luc.Fontana@u-clermont1.fr; Alain Chamoux - Alain.Chamoux@u-clermont1.fr; 
Nadège Rabiau - rabiau@soluscience.fr; Fabrice Kwiatkowski - Fabrice.KWIATKOWSKI@cjp.fr; Nasséra Chalabi - chalabi.nassera@wanadoo.fr; 
Samir Satih - samir.satih@caramail.com; Yves-Jean Bignon* - Yves-Jean.Bignon@cjp.fr
* Corresponding author    
Abstract
Breast and ovarian cancers increased in the last decades. Except rare cases with a genetic
predisposition and high penetrance, these pathologies are viewed as a polygenic disease. In this
concept, association studies look for genetic variations such as polymorphisms in low penetrance
genes, i.e. genes in interaction with environmental factors. DNA repair systems that protect the
genome from deleterious endogenous and exogenous damages have been shown to have
significantly reduced. In particular, enzymes of the nucleotide excision repair pathway are
suspected to be implicated in cancer. In this study, 2 functional polymorphisms in a DNA repair
gene ERCC2 were analyzed. The population included 911 breast cancer cases, 51 ovarian cancer
cases and 1000 controls. The genotyping of 2 SNP (Single Nucleotide Polymorphism) was carried
out on the population with the MGB (Minor Groove Binder) probe technique which consists of the
use of the allelic discrimination with the Taqman® method. This study enabled us to show an
increase in risk of breast cancer with no oral contraceptive users and with women exhibiting a
waist-to-hip ratio (WHR) > 0.85 for Asn homozygous for ERCC2 312.
Background
High levels of DNA damage, caused by excessive exposure
to carcinogens, might be responsible for increased breast
cancer susceptibility in women known to have signifi-
cantly reduced DNA repair proficiencies [1]. In particular,
dysfunctions of the nucleotide excision repair (NER)
pathway are known or suspected to be involved in cancer.
The DNA helicase encoded by the excision repair cross-
complementing group 2 gene ERCC2 (formely XPD) is
one of seven nucleotide excision repair enzymes that
cause Xeroderma Pigmentosum when mutated in germ line
[2]. Several polymorphisms have been identified in this
gene and particularly the Asp312Asn ERCC2 polymor-
phism which consists of the substitution of a G to A result-
ing in an amino acid change in the coding region, and the
Lys751Gln which consists in a A to C substitution in the
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coding region [3]. A change of amino acid is able to mod-
ify the effect of protein more or less, which can translate
by an effect on the systems of repair and consequently on
the carcinogenesis. Conflicting data on the roles of these
polymorphisms on cancer risk including breast and ovar-
ian cancers have been described [4-6].
The objective of this study was to establish the role of two
functional polymorphisms of a DNA repair gene ERCC2
in the risk of breast or ovarian cancer. We investigated the
possible interactions between these polymorphisms and
specific environmental factors (reproductive factors, body
mass index, tobacco smoking...) which could influence
the risk of cancer.
Results
Risk associated with individual SNPs
In this breast cancer population (Table 1), no significant
differences were found between breast cancer cases and
controls. A trend to the increase in breast cancer risk could
be observed with heterozygous women for the SNP at
position 312 of ERCC2 protein (OR = 1.06; 95% CI =
0.93–1.21) after adjustment for age. For ovarian cancer
(Table 2), there was no significant modification in the risk
for the two studied SNP.
Interaction between genetic factors and anthropometric/
lifestyle factors
Results concerning interactions between environmental
factors and risk of breast cancer were reported in Table 3.
Nonsmoker homozygous Asn at position 312 of ERCC2
tended towards an increase in the risk of developing
breast cancer (OR = 1.4; 95% CI = 0.98–2.02). Hetero-
zygous individuals for ERCC2 Asp312Asn which received
a hormonal replacement therapy (HRT) exhibited a risk to
develop breast cancer (OR = 1.39; 95% CI = 0.97–1.99). A
significant increase in the risk was observed for individu-
als who did not take oral contraceptives and who were
homozygous Asn at position 312 of ERCC2 (OR = 1.66;
95% CI = 1.08–2.53). An increase was observed for heter-
ozygous individuals at position 751 of ERCC2 who took
oral contraceptives (OR = 1.54; 95% CI = 1.00–2.36).
When age at first oral contraceptive use was after 23 years,
a significant increase in breast cancer risk was obtained for
heterozygous ERCC2 Lys751Gln (OR = 2.22; 95% CI =
1.15–4.29). Lastly, women with a waist-to-hip ratio
(WHR) > 0.85 and homozygous for position 312 of
ERCC2 exhibited a significant increase in the risk of breast
cancer (OR = 1.96; 95% CI = 1.12–3.43).
Concerning ovarian cancer (Table 4), a significant
increase in the risk was found for heterozygous ERCC2
Lys751Gln and who had menarche before 13 years old
(OR = 6.03; 95% CI = 1.02–35.78). Heterozygous individ-
uals ERCC2 Asp312Asn who did not take oral contracep-
tives had a significant increase in the risk of ovarian cancer
(OR = 2.16; 95% CI = 1.08–4.33). Heterozygous ERCC2
Asp312Asn with BMI > 25 exhibited a significant increase
in ovarian cancer risk (OR = 3.5; 95% CI = 1.00–12.26),
while heterozygous ERCC2 Lys751Gln with body mass
index (BMI) < 25 exhibited an upward tendency in ovar-
ian cancer risk (OR = 5.64; 95% CI = 0.93–33.99). Heter-
ozygous  ERCC2 Lys751Gln with WHR = 0.85 also
exhibited an upward tendency in the risk of ovarian can-
cer (OR = 5.68; 95% CI = 0.94–34.25).
Discussion
Nucleotide Excision Repair (NER) pathway is a key DNA
repair system. A dysfunction of this system would result in
higher cancer susceptibility because individuals would be
more exposed to carcinogens. Exogenous (cigarette
smoke, pollutants) and endogenous carcinogens are
potential breast and ovarian cancer risk factors. Above all,
exposition to estrogens seemed to be the major risk factor.
Indeed, estrogens had proliferative effects on mammary
cells and could be metabolized in potential carcinogens
and induce DNA damage [7]. Many investigations were
done concerning breast cancer risk and DNA repair poly-
morphisms. At the opposite, few studies were done with
ovarian cancer which exhibited a lower incidence but a
high mortality rate. So we studied two polymorphisms in
ERCC2 DNA repair gene because these polymorphisms
might modify the exposure of women to estrogens.
Table 1: ERCC2 Asp312Asn and ERCC2 Lys751Gln polymorphisms and breast cancer risk
Genotype Cases (%) Controls (%) OR (95%CI) ORadj* (95%CI) P value
ERCC2 Asp312Asn
Asp/Asp 403 (45) 458 (46) 1.00 (reference) 1.00 (reference)
Asp/Asn 383 (42) 418 (42) 1.04 (0.86–1.26) 1.06 (0.93–1.21)
Asn/Asn 118 (13) 118 (12) 1.14 (0.85–1.52) 1.12 (0.86–1.46) 0.68
ERCC2 Lys751Gln
Lys/Lys 121 (13) 119 (11) 1.00 (reference) 1.00
Lys/Gln 419 (46) 446 (44) 0.92 (0.69–1.23) 0.92 (0.80–1.05)
Gln/Gln 368 (40) 430 (43) 0.84 (0.63–1.12) 0.84 (0.64–1.09) 0.43
* Adjusted for ageMolecular Cancer 2008, 7:36 http://www.molecular-cancer.com/content/7/1/36
Page 3 of 7
(page number not for citation purposes)
An early age at menarche increases the risk of ovarian and
breast cancers, probably due to the prolonged exposure of
breast epithelium to endogenous hormones. Similarly a
late age at menopause is considered as a risk for cancer
because it increases the number of ovulatory cycles [8].
Concerning parity, a dual effect of pregnancy is reported.
On one hand, parity inhibits the early stages of mammary
carcinogenesis (long-term risk reduction) due to the ter-
minal differentiation of breast tissue. On the other hand,
there is a short-term risk increase because of the prolifera-
tion of breast tissue in response to high gestational hor-
mone levels which render the mammary gland more
susceptible to carcinogens [9]. Overall early pregnancy
and high parity are considered to have a protective effect
[10-13].
Oral contraceptive use was by far the most influential fac-
tor on breast cancer development. However, the hormo-
nal replacement therapy generates a prolonged exposure
to estrogens during life, leading to an increased risk of
breast and ovarian cancers. At the opposite, the estab-
lished protective effect of OC use in ovarian cancer may
also be due to the suppression of the LH peak and to a
decrease of endogenous estradiol production. If estrogens
are related to an increased risk of ovarian cancer, oral con-
traception might have some protective effect by lowering
the overall level of estrogens [14,15].
Studies of the relationship between BMI and the risk of
ovarian cancer have been inconclusive, finding either a
positive correlation [16-23], no relationship [24-31], or
negative association [32]. Our results suggested an inter-
action with menopausal status, with higher BMI being
more associated with ovarian cancer risk in premenopau-
sal women than in postmenopausal women, in agreement
with Beehler et al (2006) [33]. Greer et al (2005) showed
a slight increase in risk with weight during adulthood and
later in life, which was most apparent among nulliparous
women [34]. Fairfield et al (2002) did not find any asso-
ciation between recent BMI and risk of ovarian cancer, but
reported that a high BMI during early adulthood was asso-
ciated with an increased risk of premenopausal cancer
[26]. A case-control study reported an association
between increased BMI at age 18 and during most adult
life and ovarian cancer [23].
We found a strong relationship between waist-to-hip ratio
and the risk of ovarian cancer regardless of menopausal
status, underscoring the role of central adiposity in the
induction of ovarian cancer [35].
In addition, we studied tobacco smoking, the role of
which was very important in ovarian and breast cancers.
For ovarian and breast cancers, the role of the tobacco is
complex. Some of cigaret smoke compounds will have an
anti-estrogen effect, while others such as HAP, AAH and
N-nitrosamines will act as carcinogens by acting directly
on DNA. The lipophilic HAP are stored in fat tissues,
which include the mammary glands and tissues surround-
ing the ovaries [7].
Our results showed an increase in the risk of breast cancer
in individual heterozygous for ERCC2 Asp312Asn with
women receiving a menopause substitutive treatment and
an increased risk for ovarian cancer with no oral contra-
ceptive uses, and/or BMI > 25. For heterozygous ERCC2
Lys751Gln, an increased risk for breast cancer was found
with age at first OC use after 23 years. Heterozygous
ERCC2 Lys751Gln exhibited a higher risk for ovarian can-
cer when age at menarche was before 13 years, BMI < 25
and WHR < 0.85.
Besides, homozygous Asn for ERCC2 312 tended to have
an increase in breast cancer risk among nonsmokers, and
a significant increase in breast cancer risk among OC users
or with WHR > 0.85. It might be a combined effect
between DNA damage caused by estrogens and reduced
DNA repair proficiency with ERCC2. For the other first
results, the explanation might be a reduced DNA repair
proficiency with ERCC2 but it was found when the inter-
action between genetic factors and anthropometric/life-
style factors was considered.
Table 2: ERCC2 Asp312Asn and ERCC2 Lys751Gln polymorphisms and ovarian cancer risk
Genotype Cases (%) Controls (%) OR (95%CI) ORadj* (95%CI) P value
ERCC2 Asp312Asn
Asp/Asp 21 (41) 458 (46) 1.00 (reference) 1.00 (reference)
Asp/Asn 28 (55) 418 (42) 1.46 (0.82–2.60) 0.95 (0.62–1.45)
Asn/Asn 2 (4) 118 (12) 0.37 (0.09–1.51) 0.9 (0.39–2.12) 0.088
ERCC2 Lys751Gln
Lys/Lys 1 (2) 119 (12) 1.00 (reference) 1.00 (reference)
Lys/Gln 31 (61) 446 (45) 8.27 (1.54–44.43) 1.08 (0.70–1.66)
Gln/Gln 19 (37) 430 (43) 5.26 (0.86–32.18) 1.16 (0.49–2.75) 0.025
* Adjusted for ageMolecular Cancer 2008, 7:36 http://www.molecular-cancer.com/content/7/1/36
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Contradictory results were found in the literature. Tang et
al (2002) did not show an association between these two
SNP in ERCC2 and breast cancer risk whereas a lower A
allele frequency in ERCC2 Asp312Asn was found in a Chi-
nese population by Zhang et al (2005) [5,36]. On the con-
trary, a case-control study in Portugal revealed that
women with the Asn312Asn or the Gln751Gln genotype
presented a three-fold risk of ovarian cancer in compari-
son with heterozygous or wild-type homozygous women
[3].
Table 3: ERCC2 Asp312Asn, ERCC2 Lys751Gln polymorphisms and potential breast cancer risk factors
Nonsmokers Smokers
Genotype Cases (%) Controls (%) OR (CI 95%) P value Cases (%) Controls (%) OR (CI 95%) P value
ERCC2 Asp312Asn
Asp/Asp 283 (45) 299 (47) 1.00 (reference) 102 (42) 159 (44) 1.00 (reference)
Asp/Asn 258 (41) 270 (43) 1.01 (0.80–1.28) 111 (46) 146 (41) 1.19 (0.83–1.68)
Asn/Asn 85 (14) 64 (10) 1.4 (0.98–2.02) 0.16 29 (12) 54 (15) 0.84 (0.50–1.40) 0.36
No HRT* users HRT users
Genotype Cases (%) Controls (%) OR (CI 95%) P value Cases (%) Controls (%) OR (CI 95%) P value
ERCC2 Asp312Asn
Asp/Asp 175 (46) 137 (48) 1.00 (reference) 75 (40) 216 (47) 1.00 (reference)
Asp/Asn 152 (40) 119 (41) 1.00 (0.72–1.39) 92 (49) 191 (42) 1.39 (0.97–1.99)
Asn/Asn 54 (14) 31 (11) 1.36 (0.83–2.23) 0.44 19 (10) 50 (11) 1.09 (0.61–1.97) 0.20
No OC** users OC users
Genotype Cases (%) Controls (%) OR (CI 95%) P value Cases (%) Controls (%) OR (CI 95%) P value
ERCC2 Asp312Asn
Asp/Asp 240 (46) 215 (50) 1.00 (reference) 143 (42) 243 (43) 1.00 (reference)
Asp/Asn 208 (40) 176 (41) 1.06 (0.81–1.39) 161 (47) 242 (43) 1.13 (0.85–1.51)
Asn/Asn 74 (14) 40 (9) 1.66 (1.08–2.53) 0.061 40 (12) 78 (14) 0.87 (0.56–1.34) 0.44
ERCC2 Lys751Gln
Lys/Lys 79 (15) 39 (9) 1.00 (reference) 38 (11) 80 (14) 1.00 (reference)
Lys/Gln 223 (43) 198 (46) 0.56 (0.36–0.85) 181 (52) 248 (44) 1.54 (1.00–2.36)
Gln/Gln 222 (42) 195 (45) 0.56 (0.37–0.86) 0.018 127 (37) 235 (42) 1.14 (0.73–1.77) 0.044
Age at first OC use ≤ 23 years Age at first OC > 23 years
Genotype Cases (%) Controls (%) OR (CI 95%) P value Cases (%) Controls (%) OR (CI 95%) P value
ERCC2 Lys751Gln
Lys/Lys 23 (14) 46 (15) 1.00 (reference) 15 (8) 34 (13) 1.00 (reference)
Lys/Gln 80 (50) 145 (47) 1.10 (0.62–1.95) 101 (55) 103 (40) 2.22 (1.15–4.29)
Gln/Gln 58 (36) 115 (38) 1.01 (0.56–1.82) 0.89 69 (37) 120 (47) 1.3 (0.66–2.56) 0.008
Waist-to-hip ratio = 0.85 Waist-to-hip ratio > 0.85
Genotype Cases (%) Controls (%) OR (CI 95%) P value Cases (%) Controls (%) OR (CI 95%) P value
ERCC2 Asp312Asn
Asp/Asp 252 (46) 356 (46) 1.00 (reference) 151 (42) 102 (48) 1.00 (reference)
Asp/Asn 234 (43) 326 (42) 1.01 (0.80–1.28) 149 (42) 92 (43) 1.09 (0.76–1.57)
Asn/Asn 60 (11) 98 (13) 0.86 (0.60–1.24) 0.68 58 (16) 20 (9) 1.96 (1.12–3.43) 0.06
* HRT = Hormone Replacement Therapy
** OC = Oral ContraceptiveMolecular Cancer 2008, 7:36 http://www.molecular-cancer.com/content/7/1/36
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Conclusion
This study enabled us to show an increase in risk of breast
cancer with no oral contraceptive users and with women
exhibiting a waist-to-hip ratio superior to 0.85 for Asn
homozygous for ERCC2 312.
Subjects and Methods
Study Subjects
911 breast cancer cases and 51 ovarian cancer cases (aged
26–89 years), from the Auvergne region in France were
included. They are belonging to the COSA program
(Breast and Ovarian Cancer in the Auvergne region) that
consisted of the recruitment of identified women from
different clinics and hospitals in the Auvergne region in
France from November 1996 through November 1999.
Table 4: ERCC2 Asp312Asn, ERCC2 Lys751Gln polymorphisms and potential ovarian cancer risk factors
Age at menarche = 13 years Age at menarche > 13 years
Genotype Cases (%) Controls (%) OR (CI 95%) P value Cases (%) Controls (%) OR (CI 95%) P value
ERCC2 Lys751Gln
Lys/Lys 1 (3) 87 (13) 1.00 (reference) 0 (0) 32 (10) -
Lys/Gln 21 (57) 303 (46) 6.03 (1.02–35.78) 10 (71) 175 (52) 1.00 (reference)
Gln/Gln 15 (41) 271 (41) 4.82 (0.6–30.62) 0.14 4 (29) 127 (38) 0.55 (0.17–1.77) 0.32
No OC* users OC users
Genotype Cases (%) Controls (%) OR (CI 95%) Cases (%) Controls (%) OR (CI 95%)
ERCC2 Asp312Asn
Asp/Asp 13 (35) 215 (50) 1.00 (reference) 5 (50) 243 (43) 1.00 (reference)
Asp/Asn 23 (62) 176 (41) 2.16 (1.08–4.33) 5 (50) 242 (43) 1.00 (0.29–3.51)
Asn/Asn 1 (3) 40 (9) 0.41 (0.06–3.05) 0.032 0 (0) 78 (14) - 0.45
ERCC2 Lys751Gln
Lys/Lys 0 (0) 39 (9) - 0 (0) 80 (14) -
Lys/Gln 27 (73) 198 (46) 1.00 (reference) 4 (40) 248 (44) 1.00 (reference)
Gln/Gln 10 (27) 195 (45) 0.38 (0.18–0.78) 0.0085 6 (60) 235 (42) 1.58 (0.45–5.62) 0.7**
BMI ≤ 25 BMI >25
Genotype Cases (%) Controls (%) OR (CI 95%) Cases (%) Controls (%) OR (CI 95%)
ERCC2 Asp312Asn
Asp/Asp 18 (47) 311 (45) 1.00 (reference) 3 (23) 147 (48) 1.00 (reference)
Asp/Asn 19 (50) 292 (43) 1.12 (0.58–2.18) 9 (69) 126 (41) 3.5 (1.00–12.26)
Asn/Asn 1 (3) 84 (12) 0.21 (0.03–1.29) 0.19 1 (8) 34 (11) 1.44 (0.15–14.11) 0.13
ERCC2 Lys751Gln
Lys/Lys 1 (3) 84 (12) 1.00 (reference) 0 (0) 35 (11) -
Lys/Gln 21 (55) 313 (45) 5.64 (0.93–33.99) 10 (77) 133 (43) 1.00 (reference)
Gln/Gln 16 (42) 291 (42) 4.62 (0.72–29.53) 0.17 3 (23) 139 (45) 0.29 0.08–0.99) 0.048
Waist-to-hip ratio = 0.85 Waist-to-hip ratio > 0.85
Genotype Cases (%) Controls (%) OR (CI 95%) Cases (%) Controls (%) OR (CI 95%)
ERCC2 Lys751Gln
Lys/Lys 1 (4) 102 (13) 1.00 (reference) 0 (0) 17 (8) -
Lys/Gln 19 (70) 341 (44) 5.68 (0.94–34.25) 12 (50) 105 (49) 1.00 (reference)
Gln/Gln 7 (26) 338 (43) 2.11 (0.27–16.57) 0.02 12 (50) 92 (43) 1.14 (0.49–2.66) 0.76
* OC = Oral Contraceptive
** after Yates correctionMolecular Cancer 2008, 7:36 http://www.molecular-cancer.com/content/7/1/36
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Eligible subjects were women who had been diagnosed
with breast or ovarian cancer with no BRCA mutation and
no more than one first degree relative breast cancer.
1,000 healthy control women (aged 24–85 years) were
recruited in a mammographic screening center from July
2005 to April 2006. Eligible controls were women with no
previous history of cancer and resident in the Auvergne
region. All study subjects received counseling and pro-
vided written consent for the study.
Data collection
Participants completed a questionnaire about their medi-
cal and reproductive histories in particular. Breast and
ovarian cases filled in the questionnaire at the time of
clinic appointment whereas controls were interviewed at
the medical center at the time of enrollment. Data regard-
ing reproductive history (including gravidity, parity, age at
first-full term pregnancy, history of breastfeeding, age at
menarche and menopause, menstrual cycle regularity,
hormone replacement therapy), use of oral contraceptives
(OC) ("Ever use" of OC was defined as at least 3 months
of use), age at first OC use and duration of OC, anthropo-
metric characteristics (height, weight, weight at age 20,
waist and hip measurements), smoking status ("ever
smoker" was defined as at least 1 year of smoking) were
collected.
Genotyping
For breast and ovarian cancer patients and healthy
women, genomic DNAs were extracted from whole blood
using DNA extraction kit by Euromedex according to the
manufacturer's protocol (Euromedex, Souffelweyersheim,
France). Two functional polymorphisms of a DNA repair
gene ERCC2 were selected (Table 5). The corresponding
probes were ordered at the company Applied Biosystems.
Allelic discrimination using fluorogenic probes (5' nucle-
ase assay, Taqman®) was chosen for genotyping on the ABI
PRISM 7700 Sequence Detection Systems (Applied Bio-
systems, Foster City, CA, USA) and consisted of the use of
allele-specific fluorogenic probes [37]. Sixteen nanograms
of DNA were amplified by AmpliTaq Gold DNA polymer-
ase which was included in Taqman® Universal Master Mix
(Applied Biosystems, Foster City, CA, USA). The PCR reac-
tions were as follows: one step of 10 min at 95°C fol-
lowed by 40 cycles of two-step PCR with denaturation at
92°C for 15s and annealing and extension at 60°C for 1
min. Ten percent of all samples were genotyped again for
quality control.
Statistical Analysis
The software SEM (Centre Jean Perrin, Clermont Ferrand,
France) was used for data analyses [38]. Standard descrip-
tive statistics consisted in means plus standard deviation
for quantitative data. Comparisons between cases and
controls were performed using Chi2-squared test for qual-
itative parameters. Univariate and multivariate analyses
were performed to determine cancer risk factors in our
populations, and odds ratios (ORs) with corresponding
95% confidence interval (95% CI) were estimated.
Allelic frequencies and the distribution of genotype were
compared within the two populations using Chi2 analysis
and ORs with 95% CI. Yates correction was performed
when the number of cases was inferior to 5. The potential
confounding effects of known breast cancer risk factors
(age at menarche, number of children, age at first child
birth, menopause, breastfeeding, oral contraceptive (OC)
use, age at first OC use, body mass index [BMI], BMI at 20
years old, waist-to-hip ratio [WHR] and smoking) were
evaluated by adjusting for unconditional logistic regres-
sion and calculation of ORs. As no changes in ORs were
noted, results were reported without adjustment for these
factors.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DBG, LD was responsible for genotyping polymorphisms,
statistical analyses and interpretation, and drafting of the
manuscript; RB, NC, SS, NR contributed with the coordi-
nation of the study and helped in statistical analyses; FK
provided expertise in data analyses; YJB, DBG, LF, AC con-
tributed to the study design and manuscript preparation.
All authors participated in the preparation of the manu-
script and approved the final version.
Acknowledgements
This study was supported by "La Ligue Nationale Française de Lutte Contre 
le Cancer" (Puy-de-Dôme, Allier and Cantal). Laetitia Delort is a recipient 
of a grant from the "Association pour la Recherche sur le Cancer", Villejuif, 
France. Nasséra Chalabi is a post-graduate of the CLARA "Cancéropôle 
Lyon-Auvergne-Rhône-Alpes", France. N. Rabiau is a recipient of a grant 
"CIFRE" from Soluscience S.A., Clermont-Ferrand, France. The authors 
Table 5: Two functional polymorphisms were studied in a DNA repair gene (ERCC2)
Gene Symbols Names Studied Polymorphisms (SNP) Polymorphism NCBI References
ERCC2/XPD Excision Repair Cross-Complementing group 2 Asp312Asn [G23591A (exon 10)] rs1799793
Xeroderma Pigmentosum group D Lys751Gln [A35931C (exon 23)] rs13181Molecular Cancer 2008, 7:36 http://www.molecular-cancer.com/content/7/1/36
Page 7 of 7
(page number not for citation purposes)
wish to thank Centre République, Clermont Ferrand, France, for the enroll-
ment of control population.
References
1. Helzlsouer KJ, Harris EL, Parshad R, Perry HR, Price FM, Sanford KK:
DNA repair proficiency: potential susceptiblity factor for
breast cancer.  J Natl Cancer Inst 1996, 88:754-755.
2. Coin F, Marinoni JC, Rodolfo C, Fribourg S, Pedrini AM, Egly JM:
Mutations in the XPD helicase gene result in XP and TTD
phenotypes, preventing interaction between XPD and the
p44 subunit of TFIIH.  Nat Genet 1998, 20:184-188.
3. Costa S, Pinto D, Pereira D, Vasconcelos A, Afonso-Lopes C, Osorio
T, Lopes C, Medeiros R: Importance of xeroderma pigmento-
sum group D polymorphisms in susceptibility to ovarian can-
cer.  Cancer Lett 2007, 246:324-330.
4. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford
KK, Bell DA: XPD polymorphisms: effects on DNA repair pro-
ficiency.  Carcinogenesis 2000, 21:551-555.
5. Tang D, Cho S, Rundle A, Chen S, Phillips D, Zhou J, Hsu Y, Schnabel
F, Estabrook A, Perera FP: Polymorphisms in the DNA repair
enzyme XPD are associated with increased levels of PAH-
DNA adducts in a case-control study of breast cancer.  Breast
Cancer Res Treat 2002, 75:159-166.
6. Justenhoven C, Hamann U, Pesch B, Harth V, Rabstein S, Baisch C,
Vollmert C, Illig T, Ko YD, Bruning T, Brauch H: ERCC2 genotypes
and a corresponding haplotype are linked with breast cancer
risk in a German population.  Cancer Epidemiol Biomarkers Prev
2004, 13:2059-2064.
7. Mitrunen K, Hirvonen A: Molecular epidemiology of sporadic
breast cancer. The role of polymorphic genes involved in
oestrogen biosynthesis and metabolism.  Mutat Res 2003,
544:9-41.
8. Dumitrescu RG, Cotarla I: Understanding breast cancer risk --
where do we stand in 2005?  J Cell Mol Med 2005, 9:208-221.
9. Bernard-Gallon DJ, De Latour MP, Sylvain V, Vissac C, Aunoble B,
Chassagne J, Bignon YJ: Brca1 and Brca2 protein expression pat-
terns in different tissues of murine origin.  Int J Oncol 2001,
18:271-280.
10. Dumitrescu RG, Cotarla I: Understanding breast cancer risk -
where do we stand in 2005?  J Cell Mol Med 2005, 9:208-221.
11. Innes KE, Byers TE: First pregnancy characteristics and subse-
quent breast cancer risk among young women.  Int J Cancer
2004, 112:306-311.
12. Pathak DR: Dual effect of first full term pregnancy on breast
cancer risk: empirical evidence and postulated underlying
biology.  Cancer Causes Control 2002, 13:295-298.
13. Russo J, Russo IH: Cellular basis of breast cancer susceptibility.
Oncol Res 1999, 11:169-178.
14. Killick S, Eyong E, Elstein M: Ovarian follicular development in
oral contraceptive cycles.  Fertil Steril 1987, 48:409-413.
15. Pelucchi C, Galeone C, Talamini R, Bosetti C, Montella M, Negri E,
Franceschi S, La Vecchia C: Lifetime ovulatory cycles and ovar-
ian cancer risk in 2 Italian case-control studies.  Am J Obstet
Gynecol 2007, 196(1):83 e1-7.
16. Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ:
Body mass index, height, and the risk of ovarian cancer mor-
tality in a prospective cohort of postmenopausal women.
Cancer Epidemiol Biomarkers Prev 2002, 11:822-828.
17. Schouten LJ, Goldbohm RA, van den Brandt PA: Height, weight,
weight change, and ovarian cancer risk in the Netherlands
cohort study on diet and cancer.  Am J Epidemiol 2003,
157:424-433.
18. Hirose K, Tajima K, Hamajima N, Kuroishi T, Kuzuya K, Miura S,
Tokudome S: Comparative case-referent study of risk factors
among hormone-related female cancers in Japan.  Jpn J Cancer
Res 1999, 90:255-261.
19. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnus-
son CM, Persson IR: Risk factors for epithelial borderline ovar-
ian tumors: results of a Swedish case-control study.  Gynecol
Oncol 2001, 83:575-585.
20. Purdie DM, Bain CJ, Webb PM, Whiteman DC, Pirozzo S, Green AC:
Body size and ovarian cancer: case-control study and sys-
tematic review (Australia).  Cancer Causes Control 2001,
12:855-863.
21. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight,
obesity, and mortality from cancer in a prospectively studied
cohort of U.S. adults.  N Engl J Med 2003, 348:1625-1638.
22. Farrow DC, Weiss NS, Lyon JL, Daling JR: Association of obesity
and ovarian cancer in a case-control study.  Am J Epidemiol 1989,
129:1300-1304.
23. Lubin F, Chetrit A, Freedman LS, Alfandary E, Fishler Y, Nitzan H, Zul-
tan A, Modan B: Body mass index at age 18 years and during
adult life and ovarian cancer risk.  Am J Epidemiol 2003,
157:113-120.
24. Engeland A, Tretli S, Bjorge T: Height, body mass index, and
ovarian cancer: a follow-up of 1.1 million Norwegian women.
J Natl Cancer Inst 2003, 95:1244-1248.
25. Dal Maso L, Franceschi S, Negri E, Conti E, Montella M, Vaccarella S,
Canzonieri V, Parazzini F, La Vecchia C: Body size indices at dif-
ferent ages and epithelial ovarian cancer risk.  Eur J Cancer
2002, 38:1769-1774.
26. Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE, Hankin-
son SE: Obesity, weight gain, and ovarian cancer.  Obstet Gynecol
2002, 100:288-296.
27. Kuper H, Cramer DW, Titus-Ernstoff L: Risk of ovarian cancer in
the United States in relation to anthropometric measures:
does the association depend on menopausal status?  Cancer
Causes Control 2002, 13:455-463.
28. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni
JF, Adam HO: A prospective study of obesity and cancer risk
(Sweden).  Cancer Causes Control 2001, 12:13-21.
29. Moller H, Mellemgaard A, Lindvig K, Olsen JH: Obesity and cancer
risk: a Danish record-linkage study.  Eur J Cancer 1994,
30A:344-350.
30. Slattery ML, Schuman KL, West DW, French TK, Robison LM: Nutri-
ent intake and ovarian cancer.  Am J Epidemiol 1989,
130:497-502.
31. Anderson JP, Ross JA, Folsom AR: Anthropometric variables,
physical activity, and incidence of ovarian cancer: The Iowa
Women's Health Study.  Cancer 2004, 100:1515-1521.
32. Lukanova A, Toniolo P, Lundin E, Micheli A, Akhmedkhanov A, Muti
P, Zeleniuch-Jacquotte A, Biessy C, Lenner P, Krogh V, Berrino F,
Hallmans G, Riboli E, Kaaks R: Body mass index in relation to
ovarian cancer: a multi-centre nested case-control study.  Int
J Cancer 2002, 99:603-608.
33. Beehler GP, Sekhon M, Baker JA, Teter BE, McCann SE, Rodabaugh
KJ, Moysich KB: Risk of ovarian cancer associated with BMI
varies by menopausal status.  J Nutr 2006, 136:2881-2886.
34. Greer JB, Modugno F, Ness RB, Allen GO: Anthropometry and
the risk of epithelial ovarian cancer.  Cancer 2006,
106:2247-2257.
35. Delort L, Kwiatkowski F, Chalabi N, Satih S, Bignon YJ, Bernard-Gal-
lon DJ: Risk factors for early age at breast cancer onset--the
"COSA program" population-based study.  Anticancer Res 2007,
27:1087-1094.
36. Zhang L, Zhang Z, Yan W: Single nucleotide polymorphisms for
DNA repair genes in breast cancer patients.  Clin Chim Acta
2005, 359:150-155.
37. Livak KJ: Allelic discrimination using fluorogenic probes and
the 5' nuclease assay.  Genet Anal 1999, 14:143-149.
38. Kwiatkowski F, Girard M, Hacène K, Berlie J: Sem: a suitable sta-
tistical software adaptated for research in oncology.  Bull Can-
cer 2000, 87:715-721.